Elicio Therapeutics, Inc. (ELTX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 28 | 0 | 0 | 0 | 0 | 0 | 20 |
| Operating profit | $m | -38 | -38 | ||||||
| Net profit | $m | -80 | -26 | -28 | -35 | -52 | -40 | -38 | -29 |
| EPS reported | $ | -2.58 | -2.13 | ||||||
| Operating cashflow per share | $ | -2.41 | -1.96 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -2.41 | -1.96 | ||||||
| Free cash flow | $m | -37 | -38 | ||||||
| Net debt | $m | -9 | -14 | ||||||
| Book value equity | $m | 2 | 8 | ||||||
| Book value per share | $ | 0.11 | 0.41 | ||||||
| Number of shares | m | 15.31 | 19.24 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 74.50 | 15.36 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -3.30 | -3.23 | ||||||
| EV/EBITDA LTM | x | -3.16 | -2.91 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -32.46% | -63.63% | ||||||
| FCF Yield | % | -30.33% | -30.94% | ||||||
| Quality | |||||||||
| ROE | % | -2418.8% | -1266.4% | ||||||
| ROIC | % | -2.01% | -1.63% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.55 | -2.67 | ||||||
| Net Debt/EBITDA | x | 0.11 | 0.47 | ||||||
| EBIT/Net interest | x | -33.29 | -24.00 | ||||||
| Net debt/market cap | % | +7.72% | +7.83% | ||||||
| Net debt/Equity | x | -5.60 | -1.76 | ||||||
| Gross debt/equity | x | 8.87 | 1.78 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free